Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)

Amgen

Status: Completed

Conditions: Lung Cancer; Non-Small Cell Lung Cancer

Treatments: Other: PI Discretion

Study type: Observational

Funder types: Industry

Identifiers

NCT00094822

20030123

Details and patient eligibility

About

The purpose of this research study is to evaluate the safety and effectiveness of Neulasta® (pegfilgrastim) in reducing infection when given on the same day versus one day after the completion of chemotherapy (docetaxel and carboplatin) in patients with advanced or metastatic non-small cell lung cancer (NSCLC). This study is considered to be "investigational" because previous studies with Neulasta® used next day dosing and not same day dosing.

Enrollment: 90 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Eligibility Criteria: - Age 18 years or older - Diagnosis of advanced or metastatic non-small cell lung cancer (NSCLC) - Have not received any prior chemotherapy - Have not received radiation therapy or undergone major surgery within the past 2 weeks

Trial design

90 participants in 2 patient groups

Pegfilgrastim

Treatment:

Other: PI Discretion

PLACEBO

Treatment:

Other: PI Discretion